ReviewIrish journal of medical science2025
The intersection of ferroptosis and non-coding RNAs: a novel approach to lung cancer.
Review in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains a major global health challenge, with non-small cell lung cancer (NSCLC) accounting for nearly 85% of cases and deaths. Although advances in targeted therapy and immunotherapy have improved patient outcomes, drug resistance and limited long-term survival continue to pose serious obstacles. Ferroptosis, an iron-dependent and lipid peroxidation-driven form of regulated cell death, has attracted growing attention as a novel therapeutic approach to address these challenges. At the same time, non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs, are increasingly recognized as crucial regulators of cancer progression, therapy resistance, and cellular homeostasis. Recent studies reveal that ncRNAs and ferroptosis are closely interconnected in lung cancer, with ncRNAs influencing iron metabolism, antioxidant defense, and lipid peroxidation, thereby modulating sensitivity or resistance to ferroptotic death. Importantly, this crosstalk not only shapes tumor biology but also provides opportunities for clinical translation. Ferroptosis-related ncRNAs are emerging as potential biomarkers for prognosis, therapeutic response, and disease stratification. In addition, pharmacological induction of ferroptosis, combined with modulation of specific ncRNAs, offers a promising strategy to overcome resistance to chemotherapy, radiotherapy, and immunotherapy. This review highlights the latest advances in understanding the interplay between ncRNAs and ferroptosis in lung cancer and discusses their implications for precision medicine. By integrating ferroptosis induction with ncRNA-targeted strategies, new avenues may emerge for developing more effective and personalized therapies against NSCLC.
Indexed as
Identifiers
41034596What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.